Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab Extension Study in Japanese Patients with Periodic Fever Syndromes
NCT02911857Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2016
- Primary completion
- Jan 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of canakinumab in Tumor necrosis factor receptor associated periodic syndrome (TRAPS), Mevalonate kinase deficiency (MKD) and Familial Mediterranean fever (FMF), sponsored by Novartis. Primary endpoint: Number of Participants With Non-serious Adverse Events, Serious Adverse Events and Deaths at 3 months. Started Oct 2016; status: completed.
02
Drugs
canakinumab
03
Conditions
Tumor necrosis factor receptor associated periodic syndrome (TRAPS)Mevalonate kinase deficiency (MKD)Familial Mediterranean fever (FMF)
Beyond the preview
Go deeper on NCT02911857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02911857.